Treatment
Pozelimab clinical trials
We’re tracking 6 recruiting studies that include Pozelimab, each written for real people, not researchers, below.
Recruiting studies
- NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT07230834RecruitingPhase 1
Testing an injection for advanced dry AMD with geographic atrophy
This trial tests whether a monthly injection of pozelimab into the eye can slow the growth of geographic atrophy (a late form of dry age-related macular degeneration). It may help people who have significant vision loss from this condition.
Lakewood, ColoradoAges 50 years+ - NCT07154745RecruitingPhase 3
New combination therapy for PNH when current treatment isn't working
This trial tests a new combination of two drugs (pozelimab and cemdisiran) for adults with PNH whose current treatment (eculizumab, ravulizumab, or crovalimab) isn't controlling their symptoms well. It aims to see if the combination reduces red blood cell breakdown and improves blood counts.
Ribeirão Preto, São PauloAges 18 years+ - NCT05744921RecruitingPhase 3
Pozelizumab plus cemdisiran for adult PNH over the long term
This Phase 3 study tests whether long-term treatment with pozeli(z)umab plus cemdisiran is safe and works well in adults with paroxysmal nocturnal hemoglobinuria (PNH). It is mainly for people whose PNH does not respond to certain standard medicines or who have genetic changes that make them refractory.
Toronto, OntarioAges 18 years+ - NCT07142343RecruitingPhase 4
Testing pozelimab safety in young children with CHAPLE disease
This trial tests if pozelimab is safe for children aged 1 to 5 with CHAPLE disease, a rare condition that causes swelling, blood clots, and protein loss. If your child has active CHAPLE disease, this study may offer a new treatment option.
IstanbulAges 1–5 - NCT06479863RecruitingEarly Phase 1
Testing a new drug combo for inclusion body myositis
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
Austin, TexasAges 45–75
What Pozelimab is being studied for
Conditions with recruiting Pozelimab studies.
Common questions
- Are there clinical trials studying Pozelimab?
- Yes. Clin2 currently lists 6 recruiting studies that include Pozelimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pozelimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pozelimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pozelimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.